Drug | Generic name | Year of authorization | Type of authorization | Disease | Specification of indication |
---|---|---|---|---|---|
Gliveca | imatinib | 2002 2006 | Exceptional | 1. GIST 2. DFSP | 1. Unresectable or metastatic GISTs. 2. Unresectable or metastatic DFSP, and adults who are not eligible for surgery after disease recurrence. |
Lysodrena | mitotane | 2004 | Full | Adrenocortical carcinoma | Unresectable, metastatic or relapsed adrenocortical carcinoma. |
Sutenta | sunitinib | 2006 2006 | Conditional | 1. GIST 2. RCC | 1. Unresectable or metastatic GISTs. Used after treatment with imatinib has failed. 2. Metastatic RCC. Patients who failed to respond to or relapsed after IFN-a or IL-2 based therapy. |
Nexavara | sorafenib | 2006 2007 2014 | Full | 1. RCC 2. HCC 3. Differentiated thyroid carcinoma | 1. Advanced RCC. Patients who have failed to prior IFN-a or IL-2 based therapy. 2. Not specified. 3. Locally advanced or metastatic differentiated thyroid carcinoma refractory to RAI. |
Torisel | temsirolimus | 2007 | Full | RCC | Advanced RCC. Patients who have not previously received systemic therapy and who have at least 3 of 6 prognostic risk factors. |
Yondelis | trabectedine | 2007 2009 | Exceptional | 1. STS 2. Ovarian cancer | 1. Advanced STS, patients in which anthracyclines and ifosfamide failed, or who are unsuited to receive these agents. 2. Relapsed ovarian cancer, sensitive to platinum-based chemotherapy. Used in combination with pegylated liposomal doxorubicin. |
Mepact | mifamurtide | 2009 | Full | Osteosarcoma | High-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. Combined with post-operative multi-agent chemotherapy. |
Afinitora | everolimus | 2009 | Full | RCC | Advanced RCC when relapsed after treatment with a VEGF-targeted medicine. |
Cometriq | cabozantinib | 2014 | Conditional | Medullary thyroid cancer | Progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. |
Lynparza | olaparib | 2014 | Full | Ovarian cancer | Maintenance therapy of adult patients with platinum-sensitive relapsed BRCA-mutated ovarian cancer who are in response to platinum-based chemotherapy. |
Cyramzaa | ramucirumab | 2014 | Full | Gastric cancer | Advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Combined with paclitaxel. |
Unituxinb | dinutuximab | 2015 | Full | Neuroblastoma | Patients aged 11 months to 17 years with high-risk neuroblastoma, following myeloablative therapy and ASCT, in combination with GM-CSF, IL-2 and isotretinoin. |
Lenvima | lenvatinib | 2015 | Full | Differentiated thyroid carcinoma | Progressive, locally advanced or metastatic differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to RAI. |
Lartruvo | olaratumab | 2016 | Conditional | STS | Adult patients with advanced STS, not amenable to curative treatment with surgery or radiotherapy and not previously treated with doxorubicin. Used in combination with doxorubicin. |
Onivyde | nanoliposomal irinotecan | 2016 | Full | Pancreatic cancer | Metastatic adenocarcinoma of the pancreas, in combination with 5-FU and LV, in adult patients who have progressed following gemcitabine based therapy. |